TrialDiabetes, obesity & metabolism2026

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Shobha Bhattachar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.